When evaluating medical tests or biomarkers for disease classification, the area under the receiver-operating characteristic (ROC) curve is a widely used performance metric that does not require us to commit to a specific decision threshold. For the same type of evaluations, a different metric known as the average precision (AP) is used much more widely in the information retrieval literature. We study both metrics in some depths in order to elucidate their difference and relationship. More specifically, we explain mathematically why the AP may be more appropriate if the earlier part of the ROC curve is of interest. We also address practical matters, deriving an expression for the asymptotic variance of the AP, as well as providing real-world examples concerning the evaluation of protein biomarkers for prostate cancer and the assessment of digital versus film mammography for breast cancer screening.
Introduction
However, to answer their question, the IR community tends to rely much more heavily (though not exclusively) on another performance metric known as the average precision (AP) -see, e.g., Peng et al. (2003) and references therein. Like the AUC, the AP is another single, numeric performance metric that does not require us to commit to a decision threshold priori to the analysis. The relationship between these two threshold-free evaluation metrics seems poorly understood, though, if at all. We studied both metrics out of curiosity. After doing so, we found that, to some extent, the AP actually seems to address both criticisms (C1) and (C2) of the AUC.
We proceed as follows. In Section 2, we define various quantities of interest using a common set of notations. In Section 3, we develop some theoretical insights. More specifically, we introduce two notions, which we call stamina and momentum, and show that, for the AUC, stamina and momentum are equally important, whereas for the AP, momentum is more important. In Section 4, we address some practical issues. In particular, we show how the AP is calculated in practice, and derive its asymptotic variance. In Section 5, we provide two examples. In Section 6, we discuss various practical implications of our result. In particular, we discuss when the AP may be considered a more attractive performance metric than the AUC.
Definitions
Suppose there are a total of n subjects, some (n 1 ) of which are diseased (class 1) and the rest (n 0 = n − n 1 ) of which are not (class 0). For every subject i, a diagnostic (or screening) test produces a score, x i , which we can use to rank (or order) the subjects -e.g., a high score (large x i ) means the subject is more likely to be diseased, and vice versa. In this section, we define various concepts associated with evaluating the effectiveness of such a test. The ultimate objective, of course, is to formally define the AUC and the AP so that they can be studied together. In order to do so, it is convenient to start with the so-called hit curve.
The hit curve
Let i denote the ordered subject index, that is, x 1 ≥ x 2 ≥ ... ≥ x n . If we threshold the scores at x k , declaring all those with scores ≥ x k to be class-1 and all those with scores < x k to be class-0, we will have a confusion matrix as displayed in Table 1 , where d(k) is the number of subjects with scores ≥ x k , and (k) is the number of subjects truly belonging to class-1 out of those declared to be class-1. Clearly, (k) is a discrete function, defined only on the set of nonnegative integers up to n.
In the literature, it is also common to represent the confusion matrix (Table 1) in terms of proportions rather than in terms of counts. This is given explicitly in Table 2 , where t ≡ d(k) n , π ≡ n 1 n , and h(t) ≡ (k) n .
When n is relatively large, it is convenient to think of the function h(t), defined on the interval [0, 1], as a continuous object. In fact, we will further assume that it is differentiable almost everywhere. This allows us to use the language of calculus -i.e., differentiation and integration -to discuss various concepts. The collection of points, {(t, h(t)), t ∈ [0, 1]}, traces out a so-called hit curve. For 
simplicity, we will refer to h(t) itself as the hit curve as well. Like the ROC curve, the hit curve also is a signature of the underlying test's effectiveness. Proposition 1 below lists a few properties of the hit curve that will be useful later; proofs are given in Appendix A.
Proposition 1 Let h(t) be a hit curve (see Table 2 ), assumed to be continuous and differentiable almost everywhere. Then, (a) h(0) = 0 and h(1) = π;
Remark In what follows, we will not distinguish between and h. Whenever we write h(k), we will be referring to the quantity defined in Table 1 and thinking of it as a discrete function on the set {0, 1, 2, ..., n}. Whenever we write h(t), we will be referring to the quantity defined in Table 2 and thinking of it as a continuous function on [0, 1] , with h(t) = h(k)/n.
The AUC
Suppose we threshold the scores at x k , a level such that t × 100% of the subjects are declared to be class-1. The quantities
are called the true positive fraction (TPF) and the false positive fraction (FPF), respectivelyrefer to Tables 1-2. The ROC curve refers to the collection of points,
The AUC is simply its area underneath, defined as
Using the definitions of TPF(t) and FPF(t) above, it is straight-forward to see that
where the final step is due to Proposition 1(c).
The AP
Instead of the TPF and the FPF, the IR community often speaks of the recall and the precision. Again, suppose we threshold the scores at x k , a level such that t × 100% of the subjects are declared to be class-1. Then,
which is the same as the TPF, and
The average precision (AP) is defined as (e.g., Zhu 2004)
which can be thought of as the area under the precision versus recall curve. Using the definitions of Recall(t) and Precision(t) above, it is straight-forward to see that
Examples
For those not familiar with either of these concepts, they are often abstract and confusing enough at first sight that a few examples are warranted. For those already comfortable with the ideas, this section can be skipped.
A random test
If a diagnostic (or screening) test is random, then h(t) = πt. That is, the true positive rate stays constant at π, the overall proportion of class-1 subjects. By Eq. (3), we have
By Eq. (5), we have
A perfect test
If a diagnostic (or screening) test is perfect, then
That is, the true positive rate is 100% until all class-1 subjects have been identified, after which the true positive rate necessarily stays at zero. By Eq. (3), we have
Remarks
Notice that both the AUC and the AP, as we have defined them, are random variables, a point that will become even clearer later in Section 4. Furthermore, according to Eqs. (3) and (5), both the AUC and the AP are functionals of the hit curve h(t), a point that we will sometimes emphasize by writing AUC(h) and AP(h).
Theory
In this section, we use a simple, parametric, quasi-concave model for the hit curve to gain some important insight about the AUC and the AP.
The quasi-concave model
Consider a quasi-concave hit curve (Figure 1 ), parameterized as follows:
There are two parameters: β ∈ [π, 1] is the initial true positive rate of the underlying test, and α ∈ [0, π/β] is the change point at which the test's true positive rate drops. The requirement β ≥ π ensures that the model is describing a test that is as least as good as random; worse-thanrandom procedures are not interesting and practically irrelevant. The requirement β ≤ 1 is due to Proposition 1(b). And, finally, the requirement α ≤ π/β is because, with a true positive rate of β, all class-1 subjects will have been identified by t = π/β, leaving no more for t > π/β.
Momentum and stamina
Despite its overwhelming simplicity, there are good reasons why the quasi-concave model (6) is useful.
First, hit curves are typically concave, reflecting the fact that the true positive rate typically drops as the scores decrease -that is, higher-ranked subjects are more likely than lower-ranked ones to belong to class-1. Eq. (6) is arguably the simplest approximation possible to any concave function. When β > π, it is easy to see that the slope of the second segment, (π − αβ)/(1 − α), is smaller than that of the first segment, β, which is why we use the name "quasi-concave". This idea of using a quasi-concave function to approximate a concave function is inspired by Laibson (1997) , who used "quasi-hyperbolic" discount functions to study time-inconsistent intertemporal choices in behavioral economics.
Second, the two parameters, α and β, each capture an essential feature of the underlying diagnostic (or screening) test: α: As the change point at which the true positive rate drops, this parameter measures the stamina of the test -how long can the initial, relatively high true positive rate "last"?
β: As the initial true positive rate, this parameter measure the momentum of the test -performing at its best level, how fast can the test identify the subjects that it is supposed to identify?
Momentum-stamina trade-off
For a quasi-concave hit curve, h(t), given by Eq. (6), it is easy to see that
Figure 1: Two quasi-concave hit curves, h 1 (t) and h 2 (t), parameterized respectively by (α 1 , β 1 ) and (α 2 , β 2 ). In this illustration, the parameters α 1 , α 2 , β 1 , β 2 are configured so that AUC(h 1 ) = AUC(h 2 ) -see Theorem 1. But since β 2 > β 1 , Theorem 2 implies that AP(h 2 ) > AP(h 1 ). In practice, the initial part of the hit curve is often more relevant, which makes the AP a more useful evaluation metric.
Then, by Eq. (3),
which immediately implies Theorem 1 below.
Theorem 1 If two hit curves, h 1 (t) and h 2 (t), both belong to the quasi-concave family (6), and are parameterized respectively by (α 1 , β 1 ) and (α 2 , β 2 ), then AUC(h 1 ) = AUC(h 2 ) if and only if
Theorem 1 explains that two diagnostic (or screening) tests h 1 and h 2 can have the same AUC for different reasons. The trivial case is when both α 1 = α 2 and β 1 = β 2 ; this is when h 1 and h 2 are truly identical -same stamina and same momentum. However, if β 1 < β 2 , then Theorem 1 implies that we must necessarily have α 1 > α 2 , and vice versa. That is, on the AUC-scale, mediocre momentum can be compensated by greater stamina, and vice versa. This provides a mathematically explicit explanation for the reason behind criticism (C1), namely why two qualitatively different tests can end up having similar AUC values.
AP versus AUC
What about the AP? If h(t) is a quasi-concave hit curve given by Eq. (6), then
Using the Taylor approximation that log(α) ≈ α − 1, the expression above can be simplified to
Recall from Section 2.4 that AP(Random) = π, AP(Perfect) = 1, AUC(Random) = 1/2, and AUC(Perfect) = 1. We can rescale the AP and the AUC to both lie between 0 and 1:
and
Then,
by Eq. (8) and Eq. (12), while
by Eq. (10) and Eq. (11). These results establish Theorem 2 below.
Theorem 2 If a hit curve, h(t), belongs to the quasi-concave family (6), then
Theorem 2 suggests that, if two diagnostic (or screening) tests have the same AUC, then the AP will "reward extra points" to the one with the larger momentum (larger β). Since momentum is the initial true positive rate, this means the AP places more emphasis on the initial part of the ROC curve. Hence, the AP can be seen as being based upon the AUC but having incorporated a self-correcting factor in response to criticism (C2).
A simple simulation
The theoretical insights derived in the previous sections are based on using a quasi-concave model for the hit curve. Here, we report a simple simulation study to investigate the applicability of Theorem 2 to general hit curves, i.e., those outside the quasi-concave family, Eq. (6).
In the literature (see, e.g., Pepe 2003) , it is customary to simulate diagnostic/screening tests in the following way: Without loss of generality, scores given by the test to subjects in class-0 are simulated from f 0 (x) ∼ N(0, 1), and those given to subjects from class-1 are simulated from f 1 (x) ∼ N(∆, 1) for some ∆ > 0. How well the scores rank the subjects (in terms of the AP and/or the AUC) is then studied. The parameter, ∆, controls the strength of the simulated test -a large ∆ means the test tends to give much higher scores to subjects in class-1 than to those in class-0; it is thus a more powerful test. Given (n, π, ∆), we first generated nπ scores from N(∆, 1,) and n(1 − π) scores from N(0, 1). Using these scores, we plotted the resulting hit curve, h(t), as well as computed AP(h) and AUC(h). Then, we computed
and plotted the line f (t) = βt on top of h(t). This procedure was easily repeated for many combinations of (n, π, ∆).
Fixing n = 500, Figure 2 shows four representative scenarios, generated by all combinations of π = 0.1 (low prevalence) or π = 0.5 (high prevalence), and ∆ = 0.5 (weak test) or ∆ = 2 (strong test). Our results, including those not shown in Figure 2 , suggest that β, as given by equation (14), is a good approximation of the initial true positive rate. This, in turn, verifies that the approximate relationship (13) established by Theorem 2 is still useful even if the hit curve h(t) does not belong to the quasi-concave family (6).
Practice
While conceptually it is convenient to think of h(t) as a continuous function, in practice we are often faced with its discrete cousin, h(k). In this section, we first describe the typical set-up (Section 4.1). In Section 4.2, we derive explicit expressions for the AUC and the AP under this set-up. These expressions not only show how the AUC and the AP can be computed in practice, but they also confirm, from a slightly different point of view, our earlier result that the AP places more emphasis on initial true positives. To actually use the AP as a performance metric in practice, we need not only the AP, but also its standard error. In Section 4.3, we derive the asymptotic variance for the AP by considering the set-up given in Section 4.1. Table 3 : A diagnostic (or screening) test partitions n subjects into K groups (K distinct scores). The broken bars (¦) illustrates the case where all those with scores ≥ x k (left) are declared to be class-1, while all those with scores < x k (right) are declared to be class-0.
In general, suppose a diagnostic (or screening) test gives K distinct scores for a total of n subjects, with K ≤ n. If K < n, it means that some subjects' scores are tied. The case of "no ties" simply corresponds to the special case of K = n. With K distinct scores, the subjects are partitioned into K groups. Within each group, some may belong to class-1 and others may belong to class-0, but the test cannot distinguish them. We will use R 1 to denote the set of all subjects receiving the top score, R 2 to denote the set of all subjects receiving the next top score, and so on for R 3 , ..., R K . Furthermore, let S k = total number of subjects in R k , Z k = total number of class-1 subjects in R k , Z k = total number of class-0 subjects in R k . 
AP versus AUC, again
Under the typical set-up (Table 3) , if we threshold the scores at x k , then all those in partitions R 1 , R 2 , ..., R k will be declared class-1 and the rest, declared class-0. Therefore, we have
As a result, Eq. (3) becomes
where the term inside the curly brackets can be simplified further as follows:
Likewise, Eq. (5) becomes
Eqs. (15) and (17) give convenient and explicit expressions for how the AUC and the AP are calculated in practice. They also reveal that both the AUC and the AP can be expressed as weighted averages of Z 1 , Z 2 , ..., Z K , except that they use different weights: w k for the AUC and w k for the AP.
The difference between w k and w k can most clearly be seen in the case of "no ties", i.e., K = n. Under such circumstances, each R k contains just one subject, so S k = 1 for all k, and each Z k is either zero or one. Then, it is easy to see from Eqs. (15)- (16) and Eqs. (17)- (18) that
The main difference, therefore, is that the weights used by the AUC are independent of, whereas the ones used by the AP are adaptive to, the test itself. Suppose Z k 1 = 1 and Z k 2 = 1 both belong to class-1, where k 1 < k 2 . When calculating the AUC for two different tests, A and B, these true positives will each receive a fixed weight, (n − k 1 − 1)/n and (n − k 2 − 1)/n, respectively. For the AP, the weights they receive will depend on the strength of the test itself; in particular, if test A identified more class-1 subjects before k 1 than did test B, the relative weight on Z k 1 would be bigger for test A than for test B. This shows, from a different point of view, that the AP places more emphasis on early true positives than does the AUC.
Asymptotic variance of the AP
In order to use the AP as an evaluation metric, we need to obtain a formula for its variance, so that its standard error can be computed in practice. To derive such a formula, notice that the data in Table 3 follow the ensuing distributions:
where
and f j (x) is the distribution of the scores in class-j (j = 0, 1). In addition,
Therefore, the log-likelihood function (aside from a constant) is given by
Let ( p, q, π) denote the MLEs of (p, q, π). Then, by classical theory (e.g., Cox and Hinkley 1974) , the asymptotic variance of ( p, q, π) is simply J −1 , where J is the Fisher information matrix associated with the log-likelihood function, Eq. (22). Thus, if we can express the AP as a function of ( p, q, π), say AP = g( p, q, π), then we easily can estimate its asymptotic variance using the delta method, i.e.,
where J denotes the observed Fisher information matrix. Indeed, this can be done based on Eq. (17) and the fact that
, and π = n 1 n .
In particular, it is easy to see that
Let θ ≡ (p, q, π) and θ ≡ ( p, q, π). The calculations of
are straight-forward; details are given in Appendix B.
Examples
We now provide two illustrative examples.
Mass spectrometry data for prostate cancer
Our first example concerns protein biomarkers for prostate cancer. By analyzing serum samples obtained from the Virginia Prostate Center Tissue and Body Fluid Bank, Adam et al. (2002) identified 779 potential biomarkers using a technology called "surface-enhanced laser desorption/ionization time-of-flight mass spectrometry" (Issaq et al. 2002) . Wang and Chang (2011) used this data set to illustrate the partial AUC (see Section 1). We focused on the n 1 = 83 patients with late-stage prostate cancer (class 1) and the n 0 = 82 normal individuals (class 0) in the data set, although the original data set also included patients with early-stage cancer and patients with benign prostate hyperplasia. Figure 3 shows the AP versus the AUC for the top 15 biomarkers as ranked by the AP. We can see clearly that, while some biomarkers (e.g., 3896.614) are ranked similarly on both scales, others (e.g., 8355.562, 8141.232, 5074.164, 6949.220, 7819.751) are ranked very differently. For example, according to both the AP and the AUC, 3896.641 is a top biomarker. On the other hand, according to the AUC, there is little difference between 8355.562 and 7819.751 whereas, according to the AP, 8355.562 is more powerful. B (8141.232 and 5074.164), which scored more or less similarly on the AP-scale but very differently on the AUC-scale. We clearly can see from this figure that the two biomarkers in pair A have qualitatively different ROC curves, yet their AUC-values are very similar. This is an unmistakable case of the momentum-stamina tradeoff that we discussed in Section 3.3 -even though the areas under their ROC curves are obviously very similar, the biomarker 8355.562 also can be recognized from its ROC curve to have a much larger momentum, which is why it scored much higher on the AP-scale, since the AP awards extra points to momentum (Section 3.4). For the two biomarkers in pair B, one immediately can discern from Figure 4 that 5074.164 has a much larger area under its ROC curve (i.e., larger AUC), yet their AP-values are more or less the same -in fact, the AP of 8141.232 is slightly higher than that of 5074.164. Again, this is due to the biomarker 8141.232 having a slightly larger momentum, a fact also noticeable from the figure. Table 4 contains various standard error estimates for the top 15 biomarkers displayed in Figure 3 . Here, we can see that the asymptotic estimates (Section 4.3) do, in fact, agree closely with standard bootstrap estimates (Efron and Tibshirani 1996) . To obtain the parametric bootstrap estimates, we first estimated the multinomial models (19)- (21), and then used the estimated parameters ( p k , q k , π) to generate B = 5, 000 multinomial samples. For the nonparametric bootstrap, we simply drew B = 5, 000 bootstrap samples, each by resampling from the original data set with replacement. 
Mammography data for breast cancer
Our second example concerns the Digital Mammographic Imaging Screening Trial (DMIST; Pisano et al. 2005) , comparing digital versus film mammography for breast cancer screening. Over 42,000 women were enrolled in the trial and underwent both digital and film mammography. Using a seven-point malignancy scale, each pair of mammograms were rated separately by two independent radiologists. At 15-month follow-up, a total of 335 breast cancers were confirmed in the final cohort, and the question was: which type of mammography better predicted these cases of cancer?
We analyzed the data from Pisano et al. (2005, Table 3 ). The AUC and the AP for the two technologies are given in Table 5 , together with various standard error estimates of the AP. As in the previous example (Table 4) , the different standard error estimates are in good agreement with each other.
Overall, digital mammography fared slightly better than film mammography on the AUC-scale, but the AP favored film mammography slightly over digital mammography. Thus, depending on the performance measure, we could arrive at different conclusions about which technology was more effective for detecting breast cancer. The difference in AP (or in AUC) between the two types of mammography was relatively small. We could not test formally whether these small differences were statistically significant because the malignancy scores based on digital mammograms and those based on film mammograms were not independent, as the mammograms were taken on the same group of patients and rated by the same group of radiologists. While
estimating the covariance term, even by the bootstrap, would require us to have information about which pair of scores -one from digital and another from film mammography -was for the same patient. We didn't have such information but, given the context, it was safe to conjecture that the covariance term most likely would have been positive. Hence, by using the standard error estimates in Table 5 and letting ρ be the (unknown) correlation coefficient between AP f ilm and AP digital , we can estimate the standard error of the difference, AP f ilm − AP digital , as a function of ρ: These simple calculations suggest that a difference of about 0.166 − 0.144 = 0.022 on the AP-scale can still be statistically significant if the correlation between digital and film mammography is relatively high, which most likely is the case in reality.
The DMIST publication (Pisano et al. 2005) used the AUC as the main performance measure. Despite their enthusiasm about the effectiveness of digital mammography, the U.S. Preventive Services Task Force recently concluded that "[e]vidence is lacking for benefits of digital mammography and MRI of the breast as substitutes for film mammography" (U.S. Preventive Services Task Force 2009). The assessment provided by the AP seems to be in line with the latter conclusion.
Discussions
We have shown in Section 3 that, relative to the AUC, the AP places additional emphasis on the initial true positive rate -or simply momentum, as we have defined it in Section 3.2. In practice, when do we care more about the momentum of a test? We think the momentum is especially important when π is relatively small, that is, when the prevalence is low. This is because, when the prevalence is low, we naturally would like to avoid raising too many red flags, but for the precious few flags that we do raise (i.e., the few top-ranked cases), we'd like to have as many true positives as possible.
Most medical screening tests do indeed operate under such circumstances, i.e., low prevalence, because the purposes of these tests are to identify diseases in their early stages, when no symptoms are present, so as to facilitate early intervention with the hope to improve outcomes (Thorner and Remein 1961) . Therefore, they target a general, asymptomatic population (Raffle and Gray 2007) , among which the prevalence is typically very low. By contrast, most diagnostic tests are aimed at patients who already display some kind of symptoms, so they typically are meant for situations where the prevalence is considerably higher. For assessing screening (as opposed to diagnostic) tests, therefore, a performance metric that emphasizes the test's momentum, such as the AP, may be more attractive than a metric that treats momentum and stamina as being equally important, such as the AUC. In the breast cancer example (Section 5.2), the disease prevalence was 0.0078 at 15 months post-screening. In practice, radiologists do consider these very low prevalence numbers when assigning malignancy scores so as to avoid too many false positives (Rosenberg et al. 2006) . In other words, precision is of particular interest for screening, and clinicians may very well prefer a screening test that is favored by the AP to one that is favored by the AUC.
Sometimes, we may have conducted a case-control study (for which π ≈ 50% by design), but would like to use the case-control data to identify biomarkers for the purpose of performing future screening tests (for which π is expected to be much smaller). In such applications, it also may be much better to use the AP rather than the AUC to assess the potential biomarkers. In the prostate cancer example (Section 5.1), biomarkers were evaluated under a case-control design (n 1 = 83 ≈ 82 = n 0 ) for their potential as screening tools for prostate cancer. To see how their relative evaluations would change if the prevalence were much lower, we conducted a simple thought experiment on the two pairs of biomarkers shown in Figure 4 , and examined what would happen if we artificially inflated the number of control subjects by creating copies of each existing control subject in the data set (Table 6 ). For pair A (8355.562, 7819.751), we already have seen in Section 5.1 that the two scored similarly on the AUC-scale despite having very different ROC curves -a clear case of momentum-stamina tradeoff, and that the marker 8355.562 scored higher on the AP-scale due to its large momentum. Here, we can see that the difference between the two markers becomes even more dramatic on the AP-scale when the prevalence is reduced. For pair B (8141.232, 5074.164) , we see that, even though the marker 5074.164 scored higher on the AUC-scale, based on the case-control data, the AP is more or less indifferent between the two, but, when the prevalence is reduced, the AP can actually start to favor the other marker 8141.232 by a substantial margin.
Finally, we think the AP is useful not only for medical screening tests, but also for the risk prediction of low probability events in general. Often, models are constructed and covariates are selected in order to predict some future event in a specific population, e.g., the risk of having a cardiovascular event in the next 10 years, or the risk of having a secondary neoplasm in the next 10 years for childhood cancer survivors, and so on. One of the main objectives is to identify patients who have a high risk of developing these conditions. Since many of these events have low probabilities, meaning that the incidence rate is low, the AP may be a better performance measure than the AUC for reasons similar to those discussed above. Currently, however, prediction models and competing risk factors are almost exclusively assessed by ROC curves and more specifically, by the AUC (Buijsse et al. 2011) . Again, by direct algebraic calculations, we can obtain that
where ∇ p , ∇ q are (K − 1)-dimensional vectors with
for k = 1, ..., K − 1, and
